Diethart Reichardt, a veteran life sciences executive, is joining venture capital-backed TearScience as its top executive for European area markets.

Reichardt will be based in Germany and will oversee sales, marketing, operations and customer support in Europe, the Middle East and Africa.

TearScience has designed treatments for evaporative dry eye disease.

The company received marketing approval recently to sell its LipiFlow product in the U.S. It is designed for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.

LipiFlow will be available immediately, but on a limited basis in the U.S. through the end of 2011.

LipiFlow removes meibomian gland obstructions by applying directed energy to a patient’s eyelid during a 12-minute in-office treatment. MGD may well be the leading cause of dry eye disease throughout the world.

Reichardt worked for 20 years at Allergan, which also focused on pharmaceutical eye care.

“Given his extensive knowledge of the European eye care industry, Diethart is the perfect fit for establishing and managing TearScience’s growth in Europe,” said Tim Willis, chief executive officer and co-founder of TearScience. “Diethart has a proven track record of success in building hundred-million dollar European businesses. We welcome him to the TearScience executive team and anticipate excellent results.”

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.